Benjamin C. Creelan, MD

Dr. Creelan earned his MD from Jefferson Medical College.  He completed an Internal Medicine Residency at Thomas Jefferson University in the Department of Internal Medicine.  Dr. Creelan then completed a Hematology Oncology Fellowship at the University of South Florida at Moffitt Cancer Center and a Master's Degree in Clinical and Translational Research through the National Institute of Health K30-sponsored SPOR program. Dr. Creelan will focus on translational and clinical research, specifically the development of new immune therapies, for the treatment of lung cancers.  His research efforts aim to more effectively treat these cancers based on new insights into the biology of the disease.

Provider

Benjamin C. Creelan, MD

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Thoracic Oncology

Print Print Physician Bio

Education & Training

BOARD CERTIFICATION:
  • Medical Oncology
FELLOWSHIP:
  • University of South Florida Moffitt Cancer Center - Hematology Oncology
RESIDENCY:
  • Thomas Jefferson University, Department of Internal Medicine - Internal Medicine
MEDICAL SCHOOL:
  • Jefferson Medical College - MD
Provider

Benjamin C. Creelan, MD

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Thoracic Oncology

Print Print Physician Bio

Publications

  • Tanvetyanon T, Creelan BC, Antonia SJ. The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer. Expert Rev Anticancer Ther. 2016 Sep;16(9):903-910. Pubmedid: 27488231.
  • Ahmed KA, Creelan BC, Kim S, Dilling TJ, Perez BA. Safety and Tolerability of Extracranial Radiation Therapy and Immune Checkpoint Inhibitors Among Patients With Metastatic Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2S):S201. Pubmedid: 27675781.
  • Schabath MB, Welsh EA, Fulp WJ, Chen L, Teer JK, Thompson ZJ, Engel BE, Xie M, Berglund AE, Creelan BC, Antonia SJ, Gray JE, Eschrich SA, Chen DT, Cress WD, Haura EB, Beg AA. Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene. 2016 Jun;35(24):3209-3216. Pubmedid: 26477306. Pmcid: PMC4837098.
  • Chen L, Kurtyka CA, Welsh EA, Rivera JI, Engel BE, Muñoz-Antonia T, Yoder SJ, Eschrich SA, Creelan BC, Chiappori AA, Gray JE, Ramirez JL, Rosell R, Schabath MB, Haura EB, Chen DT, Cress WD. Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma. Oncotarget. 2016 Dec;7(50):82254-82265. Pubmedid: 27756884.
  • Tchekmedyian N, Gray JE, Creelan BC, Chiappori AA, Beg AA, Soliman H, Perez BA, Antonia SJ. Propelling Immunotherapy Combinations Into the Clinic. Oncology (Williston Park). 2015 Dec;29(12). Pubmedid: 26680224.
  • Creelan BC. Update on immune checkpoint inhibitors in lung cancer. Cancer Control. 2014 Jan;21(1):80-89. Pubmedid: 24357746.
  • Tanvetyanon T, Creelan BC, Chiappori AA. Current clinical application of genomic and proteomic profiling in non-small-cell lung cancer. Cancer Control. 2014 Jan;21(1):32-39. Pubmedid: 24357739.
  • Creelan BC, Antonia S, Noyes D, Hunter TB, Simon GR, Bepler G, Williams CC, Tanvetyanon T, Haura EB, Schell MJ, Chiappori A. Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma. J Immunother. 2013 Oct;36(8):442-450. Pubmedid: 23994887. Pmcid: PMC3846277.
  • Creelan BC, Antonia S, Bepler G, Garrett TJ, Simon GR, Soliman HH. Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer. Oncoimmunology. 2013 Mar;2(3):e23428. Pubmedid: 23802083. Pmcid: PMC3661168.
  • Creelan BC, Antonia SJ. Immunotherapy in lung cancer: "b7-bombers" and other new developments. Sem Resp Crit Care M. 2013 Dec;34(6):810-821. Pubmedid: 24258571.
  • Creelan B, Thomas K, Massis K, Davis RM. Splenic arterial embolization for idiopathic warm auto-immune haemolytic anaemia. Brit J Haematol. 2013 Apr;161(1):2. Pubmedid: 23294152.
  • Creelan B, Ferber A. A fatal case of alemtuzumab-associated interstitial pneumonitis. Am J Ther. 2008 Jan;15(1):82-84. Pubmedid: 18223357.

Provider

Benjamin C. Creelan, MD

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Thoracic Oncology

Print Print Physician Bio

Participating Trials

CLINICAL TRIAL 18431
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention:
Open

CLINICAL TRIAL 18558
A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB00100718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies
Condition: Thoracic
Intervention: Avelumab; MSB00100718C (Avelumab); PD 0360324; PF-04518600; PF-05082566 (utomilumab)
Open

CLINICAL TRIAL 18518
A Phase 2 Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line Treatment of Patients with Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
Condition: Thoracic
Intervention: Dexamethasone; Not Applicable; Rovalpituzumab Tesirine
Open

CLINICAL TRIAL 17773
A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4
Condition: Genitourinary
Intervention: ASG-22CE
Open

CLINICAL TRIAL 18522
A Phase I Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE-A10c796T in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention: MAGE-A10c796T
Open

CLINICAL TRIAL 18051
A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients with Relapsed/Refractory Metastatic Colorectal Carcinoma
Condition: Gastrointestinal Tumor
Intervention: MGD007
Open

CLINICAL TRIAL 17971
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Condition: Thoracic
Intervention: Not Applicable
Open

CLINICAL TRIAL 18855
Multicenter, Open-label, Phase 1, Dose-escalation,Cohort-expansion, First-in-Human Study of KHK2455 Administered as Monotherapy and in Combination with Mogamulizumab (KW-0761) in Adult Subjects with Locally Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: KHK2455; KW-0761 (Mogamulizumab); Mogamulizumab
Open

CLINICAL TRIAL 18197
A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: Alimta (Pemetrexed); MM-121; Not Applicable; Pemetrexed; Taxotere (docetaxel); docetaxel
Open

CLINICAL TRIAL 18503
STARTRK-2: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Condition: Thoracic
Intervention: Entrectinib
Open

CLINICAL TRIAL 18342
A Pilot Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention: G-CSF; MESNA; NY-ESO-1c259T; cyclophosphamide; cytoxan (cyclophosphamide)
Open

CLINICAL TRIAL 17986
Phase 1 Study of Mogamulizumab (KW-0761) in Combination with MEDI4736 (Durvalumab) and Mogamulizumab in Combination with Tremelimumab in Subjects with Advanced Solid Tumors
Condition: Multiple
Intervention: CP-675,206 (tremelimumab); KW-0761 (Mogamulizumab); MEDI4736 (Durvalumab); Mogamulizumab; tremelimumab
Open

CLINICAL TRIAL 18398
Novartis Pharmaceuticals trial entitled: A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC)
Condition: Thoracic
Intervention: INC280 (Capmatinib)
Open

CLINICAL TRIAL 18094
A Phase 2 Study of Transarterial Chemoperfusion Treatment with Cisplatin, Methotrexate and Gemcitabine in Patients with Unresectable Pleural Mesothelioma
Condition: Thoracic
Intervention: Gemzar (gemcitabine); cisplatin; gemcitabine; methotrexate
Open

CLINICAL TRIAL 18321
Phase I/Ib trial of single agent PBF-509 and in combination with PDR001 for patients with advanced NSCLC
Condition: Thoracic
Intervention: PBF-509; PDR001
Open

CLINICAL TRIAL 18304
A Phase II Trial of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer
Condition: Thoracic
Intervention: AZD1775; MK-1775 (AZD1775); Paraplatin (carboplatin); Taxol (paclitaxel); carboplatin; paclitaxel
Open

CLINICAL TRIAL 18212
A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant Medi4736 In Completely Resected Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: MEDI4736 (Durvalumab); Placebo
Open

CLINICAL TRIAL 18517
A Randomized, Open-Label, Active-Controlled, Phase II Study of Intravenous Anetumab Ravtansine (BAY 94-9343) or Vinorelbine in Patients with Advanced or Metastatic Malignant Pleural Mesothelioma Overexpressing Mesothelin and Progressed on First Line Platinum/Pemetrexed-Based Chemotherapy
Condition: Thoracic
Intervention: Anetumab Ravtansine (BAY 94-9343); Navelbine (Vinorelbine); Vinorelbine
Open

CLINICAL TRIAL 17908
Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer (Screening Step)
Condition: Thoracic
Intervention: 750009 (Rilotumumab); 765338 (AZD4547); 772256 (Palbociclib); AMG102 (Rilotumumab); AZD4547; BMS-936558 (Nivolumab); Dexamethasone; Erlotinib; GDC-0032 (Taselisib); Ipilimumab; MEDI4736 (Durvalumab); Nivolumab; Palbociclib; Rilotumumab; Tarceva (Erlotinib); Taxotere (docetaxel); Yervoy (Ipilimumab); docetaxel
Open

CLINICAL TRIAL 18502
A First-in-Human Study of Repeat Dosing with REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination with Other Anti-Cancer Therapies, in Patients with Advanced Malignancies
Condition: Multiple
Intervention: Alimta (Pemetrexed); GM-CSF; Leukine (GM-CSF); Not Applicable; Paraplatin (carboplatin); Pemetrexed; REGN2810; Taxol (paclitaxel); Taxotere (docetaxel); carboplatin; cyclophosphamide; cytoxan (cyclophosphamide); docetaxel; paclitaxel; sargramostatin (GM-CSF)
Open

CLINICAL TRIAL 18624
A Phase Ib, Open-Label, Dose-Escalation Study Of The Safety And Pharmacology Of Gdc-0919 Administered With Atezolizumab In Patients With Locally Advanced Or Metastatic Solid Tumors
Condition: Multiple
Intervention: Atezolizumab (Tecentriq); GDC-0919
Open

CLINICAL TRIAL 18906
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Nivolumab; TSR-022
Open

CLINICAL TRIAL 17970
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Condition: Thoracic
Intervention: Crizotinib; Placebo; Xalkori (Crizotinib)
Open

CLINICAL TRIAL 17969
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo In Patients With Completely Resected Epidermal Growth (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention: Erlotinib; Placebo; Tarceva (Erlotinib)
Open

CLINICAL TRIAL 17985
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCB024360 in Combination With MEDI4736 in Subjects With Selected Advanced Solid Tumors
Condition: Multiple
Intervention: INCB024360 (Epacadostat); MEDI4736 (Durvalumab)
Open

CLINICAL TRIAL 18391
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients with Epithelial Cancer
Condition: Thoracic
Intervention: IMMU-132
Open

CLINICAL TRIAL 18915
A Phase 1 Trial of MLN0128 (TAK-228) in Combination with Osimertinib (AZD9291) in Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
Condition: Thoracic
Intervention: AZD9291 (Osimertinib); MLN0128; Osimertinib; TAK-228 (MLN0128)
Open

CLINICAL TRIAL 18120
A Phase Ib/II, Multicenter, Open-Label Study of EGF816 in Combination with INC280 in Adult Patients with EGFR Mutated Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: EGF816; INC280 (Capmatinib)
Open

CLINICAL TRIAL 18835
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)
Condition: Thoracic
Intervention: Adriamycin (doxorubicin); PM01183 (lurbinectedin); Topotecan; Vincristine; cyclophosphamide; cytoxan (cyclophosphamide); doxorubicin
Open

CLINICAL TRIAL 18914
Consolidative Ipilimumab and Nivolumab with Thoracic Radiotherapy after Platinum Based Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer
Condition: Thoracic
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 18677
XALT3: Phase 3 Randomized Study Comparing X-396 to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Condition: Thoracic
Intervention: Crizotinib; X-396 (Ensartinib); Xalkori (Crizotinib)
Open

CLINICAL TRIAL 18393
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination with Pembrolizumab in Patients with B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, or Squamous Cell Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: MGA271; Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 18685
Phase I/II, First-in-Human, Dose-Escalation Study of X-396 in Patients with Advanced Solid Tumors and Expansion Phase in Patients with ALK+ Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: X-396 (Ensartinib)
Open

CLINICAL TRIAL 18844
A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors
Condition: Multiple
Intervention: AZD2171 (Cediranib); Cediranib (Recentin); Olaparib (Lynparza)
Open

CLINICAL TRIAL 18537
A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-B Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumours (Phase 1b) and in Recurrent or Refractory Non-Small Cell Lung Cancer or Hepatocellular Carcinoma (Phase 2)
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Galunisertib; LY2157299 (Galunisertib); Nivolumab
Open

CLINICAL TRIAL 18871
A Phase II, Open-Label, Multicenter, Single-Arm Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients with Stage IB, II, or IIIA Resectable and Untreated Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: Atezolizumab (Tecentriq)
Open

CLINICAL TRIAL 18537
A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-B Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumours (Phase 1b) and in Recurrent or Refractory Non-Small Cell Lung Cancer or Hepatocellular Carcinoma (Phase 2)
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Galunisertib; LY2157299 (Galunisertib); Nivolumab
Open

CLINICAL TRIAL 18871
A Phase II, Open-Label, Multicenter, Single-Arm Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients with Stage IB, II, or IIIA Resectable and Untreated Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: Atezolizumab (Tecentriq)
Open

CLINICAL TRIAL 18428
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention: Crizotinib; Erlotinib; Paraplatin (carboplatin); Tarceva (Erlotinib); Taxol (paclitaxel); Xalkori (Crizotinib); carboplatin; cisplatin; etoposide; paclitaxel
Open

CLINICAL TRIAL 18758
A Phase 1, Open-Label Dose Escalation Study of PF-04518600 as a Single Agent and in Combination with PF-05082566 in Patients with Selected Locally Advanced or Metastatic Carcinomas
Condition: Thoracic
Intervention: PF-04518600; PF-05082566 (utomilumab)
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).


Provider

Benjamin C. Creelan, MD

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Thoracic Oncology

Print Print Physician Bio

In the News

Video: Testimonial by lung cancer patient, Marjorie Lovelace

Video: Dr. Creelan Discusses Results of Anti-PD-L1 Antibody in Combination with Gefitinib in NSCLC

Provider

Benjamin C. Creelan, MD

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Thoracic Oncology

Print Print Physician Bio